Glioblastoma Multiforme Market Trends Analysis, Growth Opportunities and Challenges, Clinical Activities, Leading Companies, Emerging Therapies, and Epidemiology Forecast

DelveInsight has launched a new report on Glioblastoma Multiforme (GBM) Market Insights, Epidemiology, and Market Forecast-2032”. 

DelveInsight’s “Glioblastoma Multiforme (GBM) Market Insights, Epidemiology, and Market Forecast-2032″ report offer an in-depth understanding of the Glioblastoma Multiforme (GBM), historical and forecasted epidemiology as well as the Glioblastoma Multiforme (GBM) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

Some of the key facts of the Glioblastoma Multiforme (GBM) Market Report: 

  • The National Cancer Institute estimates that 22,850 adults (12,630 men and 10,280 women) were diagnosed with brain and other nervous system cancer in 2015. It also estimates that in 2015, 15,320 of these diagnoses resulted in the death 
  • According to the study by Waschke et al., (2018), approximately 7,000 new cases of malignant brain tumors arise annually in Germany with glioblastoma being the most common malignant brain tumor 
  • According to the American Association of Neurological Surgeons, GBM has an incidence of 2–3 per 100,000 adults per year and accounts for 52% of all primary brain tumors 
  • According to the American Brain Tumor Association, an estimated 24,790 new cases of primary malignant brain tumors are expected to be diagnosed in the US in 2016. About 50% of gliomas are glioblastomas with 12,120 new cases predicted 
  • As per the studies, the Gender-based epidemiology of Glioblastoma Multiforme (GBM) is more prevalent among males than in females 

Request a sample for the Report:

Key benefits of the report:

  1. Glioblastoma Multiforme (GBM) market report covers a descriptive overview and comprehensive insight of the Glioblastoma Multiforme (GBM) Epidemiology and Glioblastoma Multiforme (GBM)  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Glioblastoma Multiforme (GBM) market report provides insights on the current and emerging therapies.
  3. Glioblastoma Multiforme (GBM) market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Glioblastoma Multiforme (GBM) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Glioblastoma Multiforme (GBM) market. 

Got queries? Click here to know more about the Glioblastoma Multiforme (GBM) Market Landscape 

Glioblastoma Multiforme (GBM) Overview: 

Glioblastoma Multiforme (GBM) is the most frequently occurring type of primary tumor of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved despite the fact that innovative diagnostic strategies and new therapies have been developed. 

GBM is a grade IV glioma according to the WHO 2007 classification and is the most common and lethal primary malignancy of the central nervous system. Despite multidisciplinary treatments such as surgery, chemotherapy, and radiotherapy, the median survival time for patients with GBM is only 14.6 months. Due to its high degree of invasiveness, radical tumor resection is not curative. GBMs can be classified into primary and secondary GBMs. Primary GBM occurs de not without evidence of a less malignant precursor while Secondary GBM develops from initially low-grade diffuse astrocytoma (WHO grade II diffuse astrocytoma) or anaplastic astrocytoma (Grade III).  

Glioblastoma Multiforme (GBM) Symptoms: 

The symptoms of Glioblastoma Multiforme (GBM) include –

  • Headaches
  • Loss of appetite
  • Loss of balance
  • Trouble in walking
  • Nausea and vomiting
  • Problems in memory

Glioblastoma Multiforme (GBM) Market  

The dynamics of the Glioblastoma Multiforme (GBM) market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as 2-OHOA, Temferon, and others during the forecasted period 2019-2032. 

Learn more by requesting for sample @Glioblastoma Multiforme (GBM) Market Landscape  

Glioblastoma Multiforme (GBM) Pipeline Therapies:

  • 2-OHOA
  • ACP-196
  • Temferon
  • Selinexor

Glioblastoma Multiforme (GBM) Pipeline Key Companies:

  • Acerta Pharma BV
  • Karyopharm Therapeutics
  • CNS Pharmaceuticals
  • Laminar Pharmaceuticals

Table of Contents 

  1. Glioblastoma Multiforme (GBM) Market Report Introduction
  2. Executive Summary
  3. SWOT analysis
  4. Glioblastoma Multiforme (GBM) Patient Share (%) Overview at a Glance
  5. Glioblastoma Multiforme (GBM) Market Overview at a Glance
  6. Glioblastoma Multiforme (GBM) Disease Background and Overview
  7. Glioblastoma Multiforme (GBM) Epidemiology and Patient Population
  8. Country-Specific Patient Population of Glioblastoma Multiforme (GBM) 
  9. Glioblastoma Multiforme (GBM) Current Treatment and Medical Practices
  10. Glioblastoma Multiforme (GBM) Unmet Needs
  11. Glioblastoma Multiforme (GBM) Emerging Therapies
  12. Glioblastoma Multiforme (GBM) Market Outlook
  13. Country-Wise Glioblastoma Multiforme (GBM) Market Analysis (2018–2030)
  14. Market Access and Reimbursement of Therapies
  15. Market drivers
  16. Market barriers
  17. Appendix
  18. Glioblastoma Multiforme (GBM) Report Methodology
  19. DelveInsight Capabilities
  20. Disclaimer
  21. About DelveInsight 

Click here to read more about Glioblastoma Multiforme (GBM) Market Outlook 2032 

Related Reports: 

Glioblastoma Multiforme (GBM) Pipeline  

Glioblastoma Multiforme (GBM) Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Glioblastoma Multiforme (GBM) market. A detailed picture of the Glioblastoma Multiforme (GBM) pipeline landscape is provided, which includes the disease overview and Glioblastoma Multiforme (GBM) treatment guidelines. 

Glioblastoma Multiforme (GBM) Epidemiology 

DelveInsight’s Glioblastoma Multiforme (GBM) Epidemiology Forecast to 2032′ report delivers an in-depth understanding of the disease, historical and forecasted Glioblastoma Multiforme (GBM) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. 


Diagnostic Imaging Equipment Market

Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases.


Invasive Candidiasis Market

“DelveInsight’s ‘Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises of North America, Europe, APAC, and RoW.


Sialidosis Market 

DelveInsight’s “Sialidosis Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology as well as the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


Filgrastim Biosimilar Insight

DelveInsight’s, “Filgrastim Biosimilar Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 


Pain Management Devices Market

Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027 

Latest Reports by DelveInsight

Basal Cell Carcinoma Market | Birch Allergy Market | Bile Duct Neoplasm Market | Gingivitis MarketLupus Nephritis Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Congestive Heart Failure Market | Gingivitis Market | Lupus Nephritis Market | Erythromelalgia Market | AL Amyloidosis Market | Primordial Dwarfism Market | Breast Pumps Market | Hyperuricemia Market | Helicobacter Pylori (H. pylori) Infection Market | AIDS Dementia- Market | Follicular Lymphoma Market | Chronic Pulmonary Hypertension Market | Adrenal Crisis Market | Retinoblastoma Market | Non-Cystic Fibrosis Bronchiectasis Market | Microsatellite Stable Colorectal Cancer Market | Chondrosarcoma Market | Sialidosis Market


To know more about our Competitive Services, Click here: Pharma Competitive Intelligence


Also, take a glance at the Blogs by DelveInsight:


About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. 

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Gaurav Bora

Email: [email protected]

City: Albany

State: New York

Country: United States




Posted on

Leave a Reply

Your email address will not be published.